New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at the University Hospital Basel, the performance of the INFINITI KRAS assay has been compared to Dideoxy- and Pyrosequencing in a comparative manner, by investigating 100 colorectal carcinoma samples with known KRAS mutation status (62 mutated cases and 38 wild type cases). Targeting the epidermal growth factor receptor (EGFR) is a new therapeutic option for patients with metastatic colorectal or lung carcinoma. However, the therapy efficiency highly depends on the KRAS mutation status in the given tumor. Therefore a reliable and secure KRAS mutation testing is crucial.
The authors conclude that the INFINITI KRAS assay seems to be slightly more sensitive compared to Dideoxy- and Pyrosequencing. In addition the hands-on time to process the samples was clearly the shortest on the INFINITI.